Meet Chibawanye Ene, M.D., Ph.D.
Chibawanye I. Ene, M.D., Ph.D
Department of Neurosurgery, Division of Surgery
About Dr. Chibawanye I. Ene
Chibawanye I. Ene, M.D., Ph.D. is an assistant professor and physician-scientist in the Department of Neurosurgery with a clinical focus on complex brain tumors and research expertise in the field of immuno-oncology, particularly macrophage based therapeutic approaches for brain tumors.
He received his M.D. from Indiana University School of Medicine and his Ph.D. in
biochemistry from Cambridge University, where he explored epigenetics of neural and cancer stem cells. He subsequently completed his residency in neurosurgery at the University of Washington School of Medicine, during which he developed novel mouse models to study brain tumor immunity.
Dr. Ene completed a fellowship in Neurosurgical Oncology at The University of Texas MD Anderson Cancer Center in 2022, distinguishing himself both as a surgeon and scientist and joined the faculty the same year.
His surgical practice primarily focuses on advanced neurosurgical procedures for primary and metastatic tumors of the brain. Novel treatments for brain tumors developed in his laboratory will eventually be brought to the clinic for brain tumor patients.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Neurosurgery, Division of Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2013 | Indiana University School of Medicine, Indianapolis, Indiana, US, Medicine, MD |
| 2012 | University of Cambridge, Cambridge, GB, Biochemistry, Ph.D |
| 2004 | Wayne State College, Wayne, Nebraska, US, Biology, BS |
Postgraduate Training
| 2021-2022 | Clinical Fellowship, Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2020-2021 | Research Fellowship, Cancer Research, MD Anderson Cancer Center, Houston, Texas |
| 2019-2020 | Clinical Fellowship, Neuro-Intensive Care Unit, Harborview Medical Center, University of Washington, Seattle, Washington |
| 2013-2020 | Clinical Residency, Neurosurgery, University of Washington School of Medicine, Seattle, Washington |
Licenses & Certifications
| 2025 | American Board of Neurological Surgeons |
| 2020 | Texas Medical Board PIT License |
| 2020 | Texas Medical Board Physician License |
| 2014 | USMLE III |
| 2013 | Washington Medical Commission Physician License |
| 2013 | USMLE II CS |
| 2008 | USMLE II CK |
| 2006 | USMLE I |
Experience & Service
Administrative Appointments/Responsibilities
Chair, Brain Tumor Program Research Seminar Series Committee, Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Other Professional Positions
Co-Chair Brain Tumor Program of the Cancer Neuroscience Program Seminar Series, Neurosurgery, MD Anderson Cancer Center, Houston, TX, 2024 - Present
Intramural Institutional Committee Activities
Member, MD Anderson Medical Records Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Cranial Section Representative, Brain Tumor Program Executive Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Honors & Awards
| 2025 - Present | Diplomat of the American Board of Neurological Surgery, American Board of Neurological Surgery |
| 2024 | Fellow of the Congress of Neurological Surgeons, Congress of Neurological Surgeons |
| 2021 | Thomas H. and Mayme P. Scott Fellowship in Cancer Research (Endowed Fellowship), MD Anderson Cancer Center |
| 2020 | Caroline Ross Distinguished Trainee Award in Brain Cancer Research, University of Texas MD Anderson Cancer Center |
| 2020 | Best Clinical Research Award for Abstract, Congress of Neurological Surgery (CNS) Annual Scientific Meeting |
| 2020 | Silver Medal Award in Basic Sciences, American Academy of Neurological Surgery (AANS) /Congress of Neurological Surgery (CNS) Tumor Satellite Meeting |
| 2019 | Alpha Omega Alpha (AΩA) National Honor Medical Society, University of Washington |
| 2019 | Ronald Bittner Award for best abstract paper on brain tumor research, American Academy of Neurological Surgery (AANS) /Congress of Neurological Surgery (CNS) Annual Scientific Meeting |
| 2012 | Best Poster in Biochemistry, National Institutes of Health |
| 2008 | NIH/ Oxford/Cambridge Research Scholarship, NIH |
| 2007 | Howard Hughes Medical Institute Research Scholarship, Howard Hughes Medical Institute |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Molecular Classifications and Treatment of Gliomas. Invited. Neuro-Oncology Core Curriculum Lecture Series. Houston, Texas, US.
- 2026. Management of Brain Metastases. Invited. TANS 2026 Annual Conference. Houston, Texas, US.
- 2025. Multidisciplinary Care Discussion Panel. Invited. Neuro-Oncology Integration Retreat Agenda. Houston, Texas, US.
- 2025. The role of a neurosurgeon scientist in the fight against brain tumors. Invited. Houston, Texas, US.
- 2025. Neurosurgery. Invited. Introduction to medical science course. Houston, Texas, US.
- 2025. Using Genetically Engineered Macrophages to enhance response of Glioblastoma to immune checkpoint inhibitors. Invited. Cancer Neuroscience Program Symposium. Houston, Texas, US.
- 2025. Clinical Perspectives for a Basic Scientist Topic: (Neuro)Surgery. Invited. Houston, Texas, US.
- 2025. Brain Tumor Awareness Month Expert Panel: Primary Brain Tumors. Invited. MDA BEST. Houston, Texas, US.
- 2025. Targeting a VAMP7 driven metabolic vulnerability in melanoma brain metastasis. Invited. Melanoma Research Seminar. Houston, Texas, US.
- 2025. Synergizing Radiation Therapy with Genetically Engineered Macrophages for Glioblastoma. Invited. MD Anderson Neurosurgery Grand Rounds. Houston, Texas, US.
- 2025. Molecular Classifications and Treatment of Gliomas. Invited. Fellowship Training Program Core Curriculum Lecture Series. Houston, Texas, US.
- 2025. The path to a career combining surgery with biomedical research for brain tumors. Invited. Student National Medical Student Meeting. Houston, Texas, US.
- 2024. Integrating spatially resolved multi-omics data to uncover metabolism driven dysfunctional cellular networks driving infiltration in brain tumor patients. Invited. MD Anderson Spatial Biology Seminar. Houston, TX, US.
- 2024. Uncovering metabolic vulnerabilities in melanoma brain metastasis using the RCAS/DCT-melanoma mouse model. Invited. Brain Mets Lab Meeting. Houston, TX, US.
- 2024. Synergizing Radiation Therapy and Myeloid Therapies for Glioblastoma. Invited. Myeloid Diversity Interest Group. Houston, TX, US.
National Presentations
- 2025. Epidemiology of Malignant Brain Tumors. Invited. Congress of Neurological Surgeons Annual Meeting. Los Angeles, California, US.
- 2025. Deaf Patient with a Glioma: Unique fMRI & Awake Craniotomy Findings. Invited. ASFNR Webinar, US.
- 2025. Combining Radiation Therapy with Genetically Engineered Macrophages for Glioblastoma. Invited. DFCI/BWH NOC Multi-Disciplinary Conference, US.
- 2024. The path from INBRE to a career combining surgery with biomedical research for brain tumors. Invited. INBRE Conference. Nebraska City, Nebraska, US.
- 2024. Synergizing Radiation therapy with myeloid targeted therapy for primary and metastatic brain tumors. Invited. Grand Rounds Presentation. Bethesda, Maryland, US.
- 2023. Synergizing Radiation therapy with myeloid targeted therapy for primary and metastatic brain tumors. Invited. Grand Rounds Presentation. Roanoke, Virginia, US.
- 2023. Systemic immune correlates associated with long-term survival after Therapeutic Adenovirus (DNX-2401) plus Interferon gamma for Recurrent Glioblastoma Effect Trial (TARGET-I): a randomized phase 1b clinical trial. Conference. Society for Neuro-Oncology Annual Scientific Meeting, Vancouver, CA.
- 2023. Synergizing Radiation therapy with myeloid targeted therapy for primary and metastatic Brain tumors. Invited. Gurdon Research Conference Basic Mechanisms to Clinical Trials in Brain Tumors, Rhode Island, US.
- 2019. Anti-PD-L1 Enhances a Radiation Induced Abscopal Response in Brain Tumors. Conference. AANS/CNS Annual Scientific Meeting. San Diego, California, US.
- 2016. Safety and Efficacy of Carmustine Wafers for Metastatic Brain Tumors. Conference. Congress of Neurological Surgeons Annual Meeting. San Diego, California, US.
- 2015. Safety and Efficacy of Preoperative Tumor Embolization of Cranial Hemangioblastomas. Invited. Congress of Neurological Surgeons Annual Meeting. New Orleans, Louisiana, US.
- 2015. Safety and Efficacy of Preoperative Tumor Embolization of Cranial Hemangioblastomas. Invited. AANS/CNS Cerebrovascular Section Meeting. Nashville, Tennessee, US.
- 2012. JMJD3 as a tumor suppressor through p53 lysine demethylation. Invited. 8th Annual NIH Graduate Student Research Symposium. Bethesda, Maryland, US.
- 2008. MicroRNA profiles of differentiating neural stem cells: Implications for Glioblastoma multiforme. Invited. The Howard Hughes Medical Institute Annual Meeting. Chevy Chase, Maryland, US.
International Presentations
- 2026. Intra-operative MRI and LITT: Techniques and case selection. Invited. Liverpool Neurosurgery Oncology Masterclass. Liverpool, GB.
- 2024. Why hasn’t immunotherapy worked yet for glioblastoma. Invited. British Neuro-oncology society (BNOS) translational webinar series. Liverpool, GB.
- 2023. Immunotherapy for GBM. Invited. The Liverpool Neurosurgery Masterclass: Neuro-oncology. Liverpool, GB.
- 2011. Relevance of H3K27 Methylation in Normal Neural Stem Cells and Brain Tumor Biology. Invited. Gurdon Institute Cambridge University. Cambridge, US.
Grant & Contract Support
| Date: | 2026 - Present |
| Title: | Using IL-12 genetically engineered macrophages to overcome resistance of glioblastoma to immunotherapy |
| Funding Source: | National Institute of Health |
| Role: | PI |
| Date: | 2026 - Present |
| Title: | Using FLASH radiotherapy to enhance the durability of response of glioblastoma to immune checkpoint inhibitors |
| Funding Source: | National Institute of Health |
| Role: | PI |
| Date: | 2026 - Present |
| Title: | Using FLASH radiotherapy to enhance the durability of response of glioblastoma to immune checkpoint inhibitors |
| Funding Source: | Damon RunyonCancer Research Foundation |
| Role: | PI |
| Date: | 2025 - Present |
| Title: | Estrogen influences blood brain barrier integrity and incidence of brain metastasis from cancer |
| Funding Source: | American Association of Cancer Research (AACR) |
| Role: | PI |
| Date: | 2025 - Present |
| Title: | Tissue sensing genetically engineered macrophages for brain tumor therapy |
| Funding Source: | Harrington Discovery Institute |
| Role: | PI |
| ID: | HDI2026-SI-11855 |
| Date: | 2025 - Present |
| Title: | IL-12 Genetically engineered macrophages for reprogramming the immune microenvironment and overcoming resistance to immune checkpoint inhibitors in gliomas |
| Funding Source: | National Institutes of Health |
| Role: | PI |
| ID: | FP00024040 |
| Date: | 2025 - Present |
| Title: | Sex-related differences in the blood brain barrier and incidence of brain metastases |
| Funding Source: | National Institutes of Health |
| Role: | PI |
| ID: | 1DP2OD038523-01 |
| Date: | 2025 - Present |
| Title: | MD Anderson Brain Tumor Program (MDA BTP) Seminar Series |
| Funding Source: | National Institutes of Health |
| Role: | PI |
| Date: | 2025 - Present |
| Title: | Using Genetically Engineered Macrophages to enhance the response of Glioblastoma to immune checkpoint inhibitors |
| Funding Source: | Cancer Prevention and Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2025 - Present |
| Title: | Targeting a VAMP7 driven metabolic vulnerability in melanoma brain metastasis |
| Funding Source: | Melanoma Research Foundation Breakthrough Consortium |
| Role: | Co-PI |
| Date: | 2024 - Present |
| Title: | Major Histocompatibility Complex Gene Editing: Improving off-the-shelf availability of genetically engineered macrophage cell therapy for glioblastoma |
| Funding Source: | Cancer Prevention and Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2024 - Present |
| Title: | Major Histocompatibility Complex Gene Editing: Improving off-the-shelf availability of genetically engineered macrophage cell therapy for glioblastoma |
| Funding Source: | Yosemite-American Cancer Society |
| Role: | PI |
| Date: | 2023 - Present |
| Title: | Selective intra-arterial delivery of human induced pluripotent stem cell derived genetically engineered macrophages (HiMacs) for cell-based cancer therapy |
| Funding Source: | National Institutes of Health |
| Role: | PI |
| Date: | 2023 - Present |
| Title: | Relevance of circulating myeloid cells during systemic immunosuppression in glioblastoma |
| Funding Source: | National Institutes of Health |
| Role: | PI |
| Date: | 2022 - Present |
| Title: | Evaluating the safety and efficacy of genetically modified human macrophages for glioblastoma in a fully humanized and personalized pre-clinical neural organoid model in-vitro |
| Funding Source: | Cancer Research Institute |
| Role: | PI |
| Date: | 2022 - 2023 |
| Title: | Systemic correlates of long-term survival following Delta-24 oncolytic virus and IFN-γ for recurrent glioblastoma (Phase 1b TARGET human clinical trial) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Date: | 2022 - 2023 |
| Title: | Uncovering metabolic pathway dependencies of BRAFV600E/AKT-1 driven melanoma brain metastasis in a spontaneous and immunocompetent mouse model of brain metastasis |
| Funding Source: | MD Anderson Melanoma SPORE |
| Role: | PI |
| Date: | 2022 - Present |
| Title: | Patient specific iPSC derived macrophages or ‘iMacs’ for personalized cancer cell-based |
| Funding Source: | National Institutes of Health |
| Role: | PI |
| Date: | 2022 - 2024 |
| Title: | Relevance of genomic alterations during glioblastoma infiltration using spatially resolved and multiplexed RNA profiling of single cells |
| Funding Source: | MD Anderson |
| Role: | PI |
| Date: | 2016 - 2018 |
| Title: | Synergizing Radiation therapy and immunotherapy for malignant brain tumor |
| Funding Source: | NIH/NINDS |
| Role: | Resident Grantee |
| ID: | NS079200 |
| Date: | 2008 - 2012 |
| Title: | Relevance of H3K27 modifiers in neural stem cells and glioblastoma |
| Funding Source: | NIH/NCI |
| Role: | Fellowship Award |
| Date: | 2007 - 2008 |
| Title: | Micro-RNA Profiles of Differentiating Neural Stem Cells; Implications for Glioblastoma Multiforme |
| Funding Source: | Howard Hughes Medical Institute (HHMI) |
| Role: | Research Scholarship |
Selected Publications
Peer-Reviewed Articles
- Ha J, Wang Y, Ma Y, Wu A, Dong S, Jeong SD, Edwards JL, Chang M, Chang YT, Wang X, Dufilho M, Najarro Torres M, McCabe S, Deng W, Grippin AJ, Weinberg JS, Raza SM, DeMonte F, McCutcheon IE, Prabhu S, Ferguson SD, Ene CI, Akdemir K, Basu S, Jindal S, Schrank BR, Hu J, Goswami S, Puduvalli VK, Lang FF, Huntoon K, Sharma P, Kim BYS, Jiang W. Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastoma. Nat Commun, 2026. e-Pub 2026. PMID: 41803138.
- Muir, M, Noll, KR, Patel, RP, Prinsloo, S, Michener, H, Kumar, VA, Ene, CI, Ferguson, SD, Weinberg, J, Lang Jr, FF, Taylor, BA, Prabhu, SS. Toward data-driven surgical planning. Journal of neurosurgery 144(2):324-335, 2026. e-Pub 2026. PMID: 41135113.
- Ene CI, Singh S, Venkataraman T, Phillips LM, Long JP, Singh D, Tran ND, Tufaro F, Anand PJ, Navin N, Prabhu S, Weinberg JS, Larman HB, Gomez-Manzano C, Fueyo J, Lang FF. Systemic immune correlates of long-term survival after Delta-24-RGD based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET). Clin Cancer Res, 2026. e-Pub 2026. PMID: 41609523.
- Goethe EA, Noll KR, Srinivasan S, Suki D, Prabhu SS, Weinberg JS, Mccutcheon IE, Ene CI, Lang FF, Weathers SS, Sullaway C, Mcaleer MF, Wefel JS, Ferguson SD. Perioperative neurocognitive functioning in elderly patients undergoing awake craniotomy for high grade glioma. Neurooncol Adv 8(1):vdag009, 2026. e-Pub 2026. PMID: 41821762.
- Haisraely O, Tom MC, Perni S, Kudchadker R, Prajapati S, Zlateva Y, Weinberg JS, Yeboa DN, Li J, Ferguson SD, Alvarez-Breckenridge C, Patel CB, Ene CI, Prabhu S, Beckham TH. Cs-131 Collagen Tile Brachytherapy for Recurrent Glioblastoma: Treatment Outcomes and Toxicity. Pract Radiat Oncol 16(2):e101-e107, 2025. e-Pub 2025. PMID: 41360286.
- Teo, JM, Kumar, VA, Khalaf, A, Noll, KR, Ferguson, SD, Ene, CI, Prabhu, SS, Wintermark, M, Liu, HL. Probabilistic template matching for detecting resting-state functional MRI language network in brain tumor patients. Medical physics 52(11), 2025. e-Pub 2025. PMID: 41231662.
- Muir, M, Noll, KR, Prinsloo, S, Michener, H, Traylor, JI, Kumar, VA, Ene, CI, Ferguson, SD, Liu, HL, Weinberg, J, Lang Jr, FF, Taylor, BA, Forkel, SJ, Prabhu, SS. Preoperative Brain Mapping Predicts Language Outcomes After Eloquent Tumor Resection. Human Brain Mapping 46(15), 2025. e-Pub 2025. PMID: 41099461.
- Ramirez-Ferrer E, Zuluaga-Garcia JP, Weinberg JS, Ene CI, Raza SM, Lang FF, Kan PT, Chen SR, Young CC. Chronic subdural hematoma treatment in oncological patients: middle meningeal artery embolization versus surgical drainage. Neurosurg Focus 59(4):E14, 2025. e-Pub 2025. PMID: 41032892.
- Haisraely O, Vedala S, Al-Sharfeen A, Manzar GS, Perni S, Tom MC, Beckham TH, Wang C, Yeboa DN, Chung C, McAleer MF, Ghia AJ, Ene CI, Weathers SP, McGovern SL, Wogan CF, Roth M, Li J, De B. Glioblastoma in young adult patients: contemporary patterns of care and survival in the United States. J Neurooncol 175(1):323-331, 2025. e-Pub 2025. PMID: 40663309.
- Beckham TH, Cha EE, Rooney MK, Tom MC, Perni S, McAleer MF, Li J, Kudchadker RJ, Prajapati S, Zlateva Y, Kaya D, Ene CI, Ferguson SD, Huse JT, Prabhu SS, Weinberg JS. Cesium-131 collagen tile brachytherapy for salvage of recurrent intracranial metastases. J Neurooncol 175(1):165-174, 2025. e-Pub 2025. PMID: 40549120.
- Lang FF, Weinberg JS, Ene CI, Clark VE, Zakaria R, Al-Holou WN, Evans L, Shepard MJ, Everson RG. Introduction. Surgical management of infiltrative gliomas. Neurosurg Focus 59(2):E1, 2025. e-Pub 2025. PMID: 40749244.
- Yeboa, DN, Li, J, Lin, R, Prabhu, SS, Beckham, TH, Woodhouse, KD, Swanson, T, Weinberg, J, Wang, X, Chi, X, Ejezie, CL, Suki, D, Wang, C, Ene, CI, McCutcheon, IE, McGovern, SL, McAleer, MF, Tom, MC, Ghia, AJ, Perni, S, Jiang, W, De, BS, Chung, C, Kim, BY, O'Brien, BJ, Huse, J, Wefel, JS, Court, LE, Tawbi, H, Janku, F, Guha-Thakurta, N, Debnam, JM, Johnson, JM, Taslicay, CA, Alvarez-Breckenridge, C, Raza, SM, Heimberger, AB, DeMonte, F, North, RY, Briere, TM, de Groot, JF, Sawaya, RE, Grosshans, DR, Lang Jr, FF, Rao, G, Ferguson, SD. Therapy, Safety, and Logistics of Preoperative vs Postoperative Stereotactic Radiation Therapy. JAMA Oncology 11(8):890-899, 2025. e-Pub 2025. PMID: 40531511.
- Ma Y, Ayyadhury S, Singh S, Vashishath Y, Ozdemir C, McKee TD, Nguyen N, Basi A, Mak D, Gomez JA, Huse JT, Noor S, Winkowski D, Baird R, Weinberg JS, Lang FF, Burks JK, Bozdag S, Seeley EH, Ene CI. Integrated single cell spatial multi-omics landscape of WHO grades 2-4 diffuse gliomas identifies locoregional metabolomic regulators of glioma growth. bioRxiv, 2025. e-Pub 2025. PMID: 40654923.
- Ene, CI, Silva, E, Noll, KR, Bradshaw, ME, Connelly, K, Liu, HL, Tummala, R, Ferson, D, Lang Jr, FF, Kumar, VA. Language mapping during awake brain surgery in a deaf patient with a brain tumor. Journal of Neurosurgery: Case Lessons 9(18), 2025. e-Pub 2025. PMID: 40324327.
- Ene CI, Abi Faraj C, Beckham TH, Weinberg JS, Andersen CR, Haider AS, Rao G, Ferguson SD, Alvarez-Brenkenridge CA, Kim BYS, Heimberger AB, McCutcheon IE, Prabhu SS, Wang CM, Ghia AJ, McGovern SL, Chung C, McAleer MF, Tom MC, Perni S, Swanson TA, Yeboa DN, Briere TM, Huse JT, Fuller GN, Lang FF, Li J, Suki D, Sawaya RE. Response of treatment-naive brain metastases to stereotactic radiosurgery. Nature Communications 15(1), 2024. e-Pub 2024. PMID: 38697991.
- Shin DH, Jiang H, Gillard AG, Kim D, Fan X, Singh SK, Nguyen TT, Sohoni SS, Lopez-Rivas AR, Parthasarathy A, Ene CI, Gumin J, Lang FF, Alonso MM, Gomez-Manzano C, Fueyo J. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice. Mol Ther 32(3):722-733, 2024. e-Pub 2024. PMID: 38311852.
- Ledbetter D, Gumin J, Phillips L, Ene C, Shimizu Y, Lang FF. Facilitating Repeat Intracarotid Injections in Mouse Models by a Novel Injection Site Repair Technique. J Vis Exp 2024(205), 2024. e-Pub 2024. PMID: 38557500.
- Noll KR, Asman P, Tasnim I, Hall M, Connelly K, Swamy C, Ene C, Tummala S, Grasu RM, Liu HL, Kumar VA, Muir M, Prinsloo S, Michener H, Wefel JS, Ince NF, Prabhu SS. Intraoperative language mapping guided by real-time visualization of gamma band modulation electrocorticograms. Neurooncol Pract 11(1):92-99, 2024. e-Pub 2024. PMID: 38222047.
- Haider, AS, McCutcheon, IE, Ene, CI, Fuller, GN, Schomer, DF, Gule-Monroe, MK, DeMonte, F, Ferguson, SD, Lang Jr, FF, Prabhu, SS, Raza, SM, Suki, D, Weinberg, J, Sawaya, RE. Subependymomas of the fourth ventricle. Journal of Clinical Neuroscience 118:147-152, 2023. e-Pub 2023. PMID: 37944358.
- Haider AS, McCutcheon IE, Ene CI, Fuller GN, Schomer DF, Gule-Monroe M, DeMonte F, Ferguson SD, Lang FF, Prabhu SS, Raza SM, Suki D, Weinberg JS, Sawaya R. Subependymomas of the fourth ventricle: To operate or not to operate?. Journal of Clinical Neuroscience 118:147-152, 2023. e-Pub 2023.
- Haider AS, Ene CI, Palmisciano P, Haider M, Rao G, Ballester LY, Fuller GN. Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report. Front Oncol 13:1071792, 2023. e-Pub 2023. PMID: 37077830.
- Chen SR, Chen MM, Ene CI, Lang FF, Kan P. Perfusion-guided endovascular super-selective intra-arterial infusion for treatment of malignant brain tumors. J Neurointerv Surg 14(6):533-538, 2022. e-Pub 2022. PMID: 34824133.
- Bs, MM, Prinsloo, S, Traylor, JI, Patel, RP, Ene, CI, Tummala, S, Prabhu, SS. Transcranial magnetic stimulation tractography and the facilitation of gross total resection in a patient with a motor eloquent glioblastoma. Journal of Neurosurgery: Case Lessons 3(20), 2022. e-Pub 2022. PMID: 36303481.
- Jiang B, Murray C, Cole BL, Glover JNM, Chan GK, Deschenes J, Mani RS, Subedi S, Nerva JD, Wang AC, Lockwood CM, Mefford HC, Leary SES, Ojemann JG, Weinfeld M, Ene CI. Mutations of the DNA repair gene PNKP in a patient with microcephaly, seizures, and developmental delay (MCSZ) presenting with a high-grade brain tumor. Sci Rep 12(1):5386, 2022. e-Pub 2022. PMID: 35354845.
- Muir M, Prinsloo S, Michener H, Shetty A, de Almeida Bastos DC, Traylor J, Ene CI, Tummala S, Kumar VA, Prabhu SS. Transcranial magnetic stimulation (TMS) seeded tractography provides superior prediction of eloquence compared to anatomic seeded tractography. Neurooncol Adv 4(1):vdac126, 2022. e-Pub 2022. PMID: 36128584.
- Abecassis IJ, Zeeshan Q, Feroze AH, Ene C, Vellimana AK, Sekhar LN. Subtemporal, Transapical, and Transcavernous Approach to Clip Low-Lying Basilar Tip Aneurysm: 2-Dimensional Operative Video. Oper Neurosurg (Hagerstown) 20(6):E436, 2021. e-Pub 2021. PMID: 33548927.
- Ene CI, Wang AC, Collins KL, Bonow RH, McGrath LB, Durfy SJ, Barber JK, Ellenbogen RG. Expansile duraplasty and obex exploration compared with bone-only decompression for Chiari malformation type I in children: retrospective review of outcomes and complications. J Neurosurg Pediatr 27(1):1-8, 2020. e-Pub 2020. PMID: 33126216.
- Ene CI, Kurnik N, Vellimana AK, Liu Y, Susarla SM, Sekhar LN. Microsurgical Resection of a Primary Intraosseous Meningioma Encasing the Superior Sagittal Sinus. J Craniofac Surg 31(7):2012-2014, 2020. e-Pub 2020. PMID: 32657980.
- Ene CI, Cimino PJ, Fine HA, Holland EC. Incorporating genomic signatures into surgical and medical decision-making for elderly glioblastoma patients. Neurosurg Focus 49(4):E11, 2020. e-Pub 2020. PMID: 33002863.
- Brempelis KJ, Cowan CM, Kreuser SA, Labadie KP, Prieskorn BM, Lieberman NAP, Ene CI, Moyes KW, Chinn H, DeGolier KR, Matsumoto LR, Daniel SK, Yokoyama JK, Davis AD, Hoglund VJ, Smythe KS, Balcaitis SD, Jensen MC, Ellenbogen RG, Campbell JS, Pierce RH, Holland EC, Pillarisetty VG, Crane CA. Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33115946.
- Ene CI, Kreuser SA, Jung M, Zhang H, Arora S, White Moyes K, Szulzewsky F, Barber J, Cimino PJ, Wirsching HG, Patel A, Kong P, Woodiwiss TR, Durfy SJ, Houghton AM, Pierce RH, Parney IF, Crane CA, Holland EC. Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma. Neuro Oncol 22(5):639-651, 2020. e-Pub 2020. PMID: 31793634.
- Ma Z, Niu B, Phan TA, Stensjøen AL, Ene C, Woodiwiss T, Wang T, Maini PK, Holland EC, Tian JP. Stochastic growth pattern of untreated human glioblastomas predicts the survival time for patients. Sci Rep 10(1):6642, 2020. e-Pub 2020. PMID: 32313150.
- Feroze AH, McGrath M, Williams JR, Young CC, Ene CI, Buckley RT, Cole BL, Ojemann JG, Hauptman JS. Laser interstitial thermal therapy for pediatric atypical teratoid/rhabdoid tumor: case report. Neurosurg Focus 48(1):E11, 2020. e-Pub 2020. PMID: 31896085.
- Parker Kerrigan BC, Ledbetter D, Kronowitz M, Phillips L, Gumin J, Hossain A, Yang J, Mendt M, Singh S, Cogdell D, Ene C, Shpall E, Lang FF. RNAi technology targeting the FGFR3-TACC3 fusion breakpoint: an opportunity for precision medicine. Neurooncol Adv 2(1):vdaa132, 2020. e-Pub 2020. PMID: 33241214.
- Yoda RA, Marxen T, Longo L, Ene C, Wirsching HG, Keene CD, Holland EC, Cimino PJ. Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma. J Neuropathol Exp Neurol 78(11):1002-1010, 2019. e-Pub 2019. PMID: 31529048.
- Zhang F, Parayath NN, Ene CI, Stephan SB, Koehne AL, Coon ME, Holland EC, Stephan MT. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat Commun 10(1):3974, 2019. e-Pub 2019. PMID: 31481662.
- Ene CI, Macomber MW, Barber JK, Ferreira MJ, Ellenbogen RG, Holland EC, Rockhill JK, Silbergeld DL, Halasz LM. Patterns of Failure After Stereotactic Radiosurgery for Recurrent High-Grade Glioma: A Single Institution Experience of 10 Years. Neurosurgery 85(2):E322-E331, 2019. e-Pub 2019. PMID: 30576476.
- Wirsching HG, Zhang H, Szulzewsky F, Arora S, Grandi P, Cimino PJ, Amankulor N, Campbell JS, McFerrin L, Pattwell SS, Ene C, Hicks A, Ball M, Yan J, Zhang J, Kumasaka D, Pierce RH, Weller M, Finer M, Quéva C, Glorioso JC, Houghton AM, Holland EC. Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma. JCI Insight 4(13), 2019. e-Pub 2019. PMID: 31292299.
- Wang AC, Jones DTW, Abecassis IJ, Cole BL, Leary SES, Lockwood CM, Chavez L, Capper D, Korshunov A, Fallah A, Wang S, Ene C, Olson JM, Geyer JR, Holland EC, Lee A, Ellenbogen RG, Ojemann JG. Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations. Mol Cancer Res 16(10):1491-1498, 2018. e-Pub 2018. PMID: 30006355.
- Zhang F, Stephan SB, Ene CI, Smith TT, Holland EC, Stephan MT. Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies. Cancer Res 78(13):3718-3730, 2018. e-Pub 2018. PMID: 29760047.
- Morton RP, Abecassis IJ, Hanson JF, Barber JK, Chen M, Kelly CM, Nerva JD, Emerson SN, Ene CI, Levitt MR, Chowdhary MM, Ko AL, Chesnut RM. Timing of cranioplasty: a 10.75-year single-center analysis of 754 patients. J Neurosurg 128(6):1648-1652, 2018. e-Pub 2018. PMID: 28799868.
- Ene CI, Morton RP, Kelly CM, Levitt MR, Ghodke B. Angiographic perfusion imaging of intracranial stenting. J Clin Neurosci 48:100-102, 2018. e-Pub 2018. PMID: 29183679.
- Morton RP, Abecassis IJ, Hanson JF, Barber J, Nerva JD, Emerson SN, Ene CI, Chowdhary MM, Levitt MR, Ko AL, Dellit TH, Chesnut RM. Predictors of infection after 754 cranioplasty operations and the value of intraoperative cultures for cryopreserved bone flaps. J Neurosurg 125(3):766-70, 2016. e-Pub 2016. PMID: 26771856.
- Ene CI, Xu D, Morton RP, Emerson S, Levitt MR, Barber J, Rostomily RC, Ghodke BV, Hallam DK, Albuquerque FC, McDougall CG, Sekhar LN, Ferreira M, Kim LJ, Chang SW. Safety and Efficacy of Preoperative Embolization of Intracranial Hemangioblastomas. Oper Neurosurg (Hagerstown) 12(2):135-140, 2016. e-Pub 2016. PMID: 29506092.
- Ene CI, Nerva JD, Morton RP, Barkley AS, Barber JK, Ko AL, Silbergeld DL. Safety and efficacy of carmustine (BCNU) wafers for metastatic brain tumors. Surg Neurol Int 7(Suppl 11):S295-9, 2016. e-Pub 2016. PMID: 27217968.
- Ene CI, Morton RP, Ferreira M, Sekhar LN, Kim LJ. Spontaneous Hemorrhage from Central Nervous System Hemangioblastomas. World Neurosurg 83(6):1180.e13-7, 2015. e-Pub 2015. PMID: 25727302.
- Ene C, Silbergeld D. Predicting survival of patients with brain metastasis. World Neurosurgery 83(4):490-1, 2015. e-Pub 2015. PMID: 25219584.
- Ene CI, Silbergeld DL. Predicting prognosis of brain metastasis using molecular and clinical variables. World Neurosurg 83(4):490-1, 2015. e-Pub 2015. PMID: 25219584.
- Ene CI, Holland EC. Personalized medicine for gliomas. Surg Neurol Int 6(Suppl 1):S89-95, 2015. e-Pub 2015. PMID: 25722938.
- Chowdhary MM, Ene CI, Silbergeld DL. Treatment of Gliomas: How did we get here?. Surg Neurol Int 6(Suppl 1):S85-8, 2015. e-Pub 2015. PMID: 25722937.
- Ene CI, Edwards L, Riddick G, Baysan M, Woolard K, Kotliarova S, Lai C, Belova G, Cam M, Walling J, Zhou M, Stevenson H, Kim HS, Killian K, Veenstra T, Bailey R, Song H, Zhang W, Fine HA. Histone demethylase Jumonji D3 (JMJD3) as a tumor suppressor by regulating p53 protein nuclear stabilization. PLoS One 7(12):e51407, 2012. e-Pub 2012. PMID: 23236496.
- Ene CI, Fine HA. Many tumors in one: a daunting therapeutic prospect. Cancer Cell 20(6):695-7, 2011. e-Pub 2011. PMID: 22172718.
- Edwards LA, Woolard K, Son MJ, Li A, Lee J, Ene C, Mantey SA, Maric D, Song H, Belova G, Jensen RT, Zhang W, Fine HA. Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J Natl Cancer Inst 103(15):1162-78, 2011. e-Pub 2011. PMID: 21771732.
- Lee J, Son MJ, Woolard K, Donin NM, Li A, Cheng CH, Kotliarova S, Kotliarov Y, Walling J, Ahn S, Kim M, Totonchy M, Cusack T, Ene C, Ma H, Su Q, Zenklusen JC, Zhang W, Maric D, Fine HA. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 13(1):69-80, 2008. e-Pub 2008. PMID: 18167341.
Review Articles
- Hasanov E, Yeboa DN, Tucker MD, Swanson TA, Beckham TH, Rini B, Ene CI, Hasanov M, Derks S, Smits M, Dudani S, Heng DYC, Brastianos PK, Bex A, Hanalioglu S, Weinberg JS, Hirsch L, Carlo MI, Aizer A, Brown PD, Bilen MA, Chang EL, Jaboin J, Brugarolas J, Choueiri TK, Atkins MB, McGregor BA, Halasz LM, Patel TR, Soltys SG, McDermott DF, Elder JB, Baskaya MK, Yu JB, Timmerman R, Kim MM, Mut M, Markert J, Beal K, Tannir NM, Samandouras G, Lang FF, Giles R, Jonasch E. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA Cancer J Clin 72(5):454-489, 2022. e-Pub 2022. PMID: 35708940.
- Ene CI, Ferguson SD. Surgical Management of Brain Metastasis: Challenges and Nuances. Front Oncol 12:847110, 2022. e-Pub 2022. PMID: 35359380.
- Wang S, Sun MZ, Abecassis IJ, Weil AG, Ibrahim GM, Fallah A, Ene C, Leary SES, Cole BL, Lockwood CM, Olson JM, Geyer JR, Ellenbogen RG, Ojemann JG, Wang AC. Predictors of mortality and tumor recurrence in desmoplastic infantile ganglioglioma and astrocytoma-and individual participant data meta-analysis (IPDMA). J Neurooncol 155(2):155-163, 2021. e-Pub 2021. PMID: 34613581.
- Palmisciano P, Haider AS, Nwagwu CD, Wahood W, Yu K, Ene CI, O'Brien BJ, Aoun SG, Cohen-Gadol AA, El Ahmadieh TY. The Role of Immune Checkpoint Inhibitors in Leptomeningeal Disease: A Systematic Review. Anticancer Res 41(11):5333-5342, 2021. e-Pub 2021. PMID: 34732403.
- Ene CI, Fueyo J, Lang FF. Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerations. Neurosurg Focus 50(2):E6, 2021. e-Pub 2021. PMID: 33524949.
- Srinivasan VM, Ene C, Kerrigan BP, Lang FF. Window of Opportunity Clinical Trials to Evaluate Novel Therapies for Brain Tumors. Neurosurg Clin N Am 32(1):93-104, 2021. e-Pub 2021. PMID: 33223031.
- Pan J, Barros G, Greil ME, Meyer RM, Ene CI, Chesnut RM. Pseudoaneurysm of the Superficial Temporal Artery After Intracranial Pressure Monitoring Device Placement: Case Report of a Rare Complication. Oper Neurosurg (Hagerstown) 19(3):288-291, 2020. e-Pub 2020. PMID: 32503046.
- Ene C, Kaul A, Kim L. Natural history of cerebral cavernous malformations. Handb Clin Neurol 143:227-232, 2017. e-Pub 2017. PMID: 28552144.
- Ene CI, Nerva JD, McGrath L, Flanagan ME, Chamberlain MC, Silbergeld DL. Flow-Related Aneurysm within Glioblastoma: A Case Report and Review of Literature. World Neurosurg 89:729.e1-6, 2016. e-Pub 2016. PMID: 26851739.
Abstracts
- Ma Y, Nguyen N, Singh S, Basi A, Mak D, Gomez J, Burks J, Seely E, Lang F, Ene C. Integrating spatially resolved multi-omics data to uncover dysfunctional metabolism driven networks that enhance infiltration of diffuse gliomas. Society for NeuroOncology Annual Meeting.
- Ma Y, Nguyen N, He W, Singh S, Fu R, Zhang L, Holmen S, Jones P, Davies M, Xu H, Ene C. Functional genomics in vivo using CRISPR/Cas9 identifies potential metabolic vulnerabilities within melanoma brain metastasis. Society for Neuro-Oncology Annual Scientific Meeting.
Book Chapters
- Ene, CI, Feroze, AH, Holland, EC. Molecular Genetics and the Development of Targets for Glioma Therapy, 931-943.e2, 2023.
- McCutcheon I, Ene C. Neurosurgical Malignancies: Treating Tumors of Brain and Spine and Their Effects on the Nervous System. In: MD Anderson Surgical Handbook, 2022.
- Ene C, Feroze A, Holland EC. Molecular Genetics and the Development of Targets for Gliomas. In: Youmans Neurological Surgery, 2019.
- Ene C, Kaul A, Kim L. Natural history of cerebral cavernous malformations. In: Handbook of Clinical Neurology, 2017.
- Ravanpay A, Ene C, Holland EC. Molecular Genetics and the Development of Targets for Gliomas. In: Youmans Neurological Surgery, 2014.
Patient Reviews
CV information above last modified March 23, 2026